GLP Peptides Pulled by Major Vendors as Compliance Pressure Accelerates

Earlier this month, we reported that Peptide Sciences had removed all major GLP-1 and next-generation metabolic peptides from its catalog, raising questions about whether the research peptide industry was entering a new enforcement phase.

That analysis is detailed in our prior article, PeptideSciences Removes GLP-1 Peptides, Industry Crackdown Concerns Escalate. At the time, the conclusion was based largely on observable vendor behavior, not official statements.

Since then, two major developments have occurred. Both Peptide Sciences and Modern Aminos have now issued direct communications confirming that GLP-related research products are being discontinued explicitly due to evolving compliance and regulatory expectations.

PeptideSciences Confirms Compliance-Driven Discontinuations

Peptide Sciences has issued a direct statement to Peptide Critic acknowledging that it has discontinued several high-profile compounds as part of routine compliance updates and alignment with evolving industry guidance.

“We want to let you know that we have discontinued several items, including Semaglutide, Tirzepatide, Retatrutide, and MK-677, as part of our routine compliance updates and alignment with evolving industry compliance guidance.”

“This was a proactive business decision and not related to any issue with the materials. We regularly review our catalog to ensure it reflects our internal standards and long-standing quality framework.”

While framed as proactive and routine, the scope of the products removed is notable. These are not fringe peptides, they are the most commercially significant, injectable, pharma-adjacent compounds in the research market.

Modern Aminos Notifies Affiliates of GLP Pullback

Shortly after the Peptide Sciences confirmation, Modern Aminos distributed an announcement to its affiliate network outlining a similar decision.

In that communication, Modern Aminos stated that regulatory expectations and compliance standards are evolving and that changes were necessary to ensure long-term sustainability of the business.

“As regulatory expectations and compliance standards continue to evolve, we’ve had to make several difficult decisions to ensure Modern Aminos can continue operating responsibly and sustainably for years to come.”

“Because of these changes, we have decided to discontinue the following GLP-related research products, effective December 31st, or earlier if inventory sells out.”

The discontinued product categories include GLP, GLP/GIP, GLP/GIP/Glucagon, cagrilintide, and Cagrisema Sodium, overlapping directly with the same high-risk classes removed by other vendors.

Why These Statements Matter

This update shifts the story from inference to confirmation.

What was previously deduced from vendor behavior is now being stated directly: large, established peptide suppliers are intentionally exiting GLP-related product categories due to compliance and regulatory pressure.

• Both vendors explicitly cite evolving compliance expectations.
• Both actions target injectable, pharma-adjacent peptides.
• Neither attributes the decision to quality, supply, or demand issues.
• Both emphasize long-term business sustainability.

This strongly suggests that risk tolerance across the industry has shifted, particularly for products that closely resemble approved or near-approved pharmaceutical drugs.

Context From the Earlier Peptide Sciences Report

In our earlier reporting, we noted that vendor behavior is often the most reliable signal in loosely regulated markets. Large suppliers do not voluntarily walk away from their most profitable products without a compelling reason.

The subsequent statements from Peptide Sciences and Modern Aminos reinforce that conclusion. This is not a rumor cycle or isolated decision. It is a coordinated retreat from categories that now carry elevated legal or regulatory exposure.

The Bottom Line

GLP-related research peptides are being actively removed from mainstream vendor catalogs, not quietly, not accidentally, and not due to material issues.

Peptide Sciences and Modern Aminos have now confirmed what the market has been signaling for months: the window for openly selling injectable, pharma-adjacent peptides through public storefronts is narrowing.

Whether this evolves into formal enforcement actions or remains a slow compliance squeeze, the research peptide landscape has already changed. The most important evidence is not speculation, but the decisions vendors are making in real time.